Risk-Benefit Assessment of Therapies for Mycobacterium avium Complex Infections
- 1 January 1999
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 21 (2) , 137-152
Abstract
Mycobacterium aviumcomplex (MAC) is an important pathogen that can cause chronic lung disease in immunocompetent patients and disseminated disease in patients with the acquired immunodeficiency...Keywords
This publication has 47 references indexed in Scilit:
- Initial (6-Month) Results of Three-Times-Weekly Azithromycin in Treatment Regimens for Mycobacterium avium Complex Lung Disease in Human Immunodeficiency Virus-Negative PatientsThe Journal of Infectious Diseases, 1998
- A Randomized Evaluation of Ethambutol for Prevention of Relapse and Drug Resistance during Treatment ofMycobacterium aviumComplex Bacteremia with Clarithromycin‐Based Combination TherapyThe Journal of Infectious Diseases, 1997
- Reduced Serum Levels Of Clarithromycin In Patients Treated With Multi-Drug Regimens Including Rifampin Or Rifabutin For Mycobacterium Avium-M. Intracellulare InfectionThe Journal of Infectious Diseases, 1995
- The Impact Of Mycobacterium AviumComplex Bacteremia And Its Treatment On Survival Of Aids Patients-A Prospective StudyThe Journal of Infectious Diseases, 1994
- Uveitis and Pseudojaundice During a Regimen of Clarithromycin, Rifabutin, and EthambutolNew England Journal of Medicine, 1994
- The new macrolides. Azithromycin and clarithromycin.1994
- Intracellular accumulation of azithromycin by cultured human fibroblastsAntimicrobial Agents and Chemotherapy, 1990
- Dose-limiting toxicity of rifabutin in AIDS-related complexAIDS, 1990
- Treatment of Disease Due to Mycobacterium intracellulareClinical Infectious Diseases, 1981
- Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex.Thorax, 1981